Adamas Pharmaceuticals reported 576K in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US $ 4341M 157M
Acadia Pharmaceuticals ACAD:US $ 6.68M 1.48M
Acorda Therapeutics ACOR:US $ 13.3M 1.98M
Adamas Pharmaceuticals ADMS:US 576K 49K
Aerie Pharmaceuticals AERI:US $ 7.9M 1.72M
Biocryst Pharmaceuticals BCRX:US $ 0.62M 0.27M
Flexion Therapeutics FLXN:US $ 3.73M 1.25M
Glaxosmithkline GSK:US $ 2822M 303M
GlaxoSmithKline GSK:LN 2822M 303M
Gw Pharmaceuticals GWPH:US $ 11.81M 1.39M
Heron Therapeutics HRTX:US $ 11.35M 3.17M
Intra Cellular Therapies ITCI:US $ 2M 0.04M
Merk MRK:US $ 3056M 14M
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Novartis NOVN:VX SF 3848M 94M
Omeros OMER:US $ 333K 9K
Revance Therapeutics RVNC:US $ 5.89M 460K
Teva Pharmaceutical TEVA:IT 1.99B 2M
Zogenix ZGNX:US $ 1.29M 0.07M